Login / Signup

Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain.

Arti ThakerarSeamus Dines-MuntanerTijana TrifunovichMarliese AlexanderSonia Fullerton
Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
In this real-world study, parecoxib was utilised as adjunctive therapy in a select patient cohort to contribute to reduced pain scores with no new safety signals. Prospective randomised studies in larger cohorts would improve understanding of the effects of parecoxib.
Keyphrases